These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2483013)

  • 1. Identification of virus neutralizing epitopes on naturally occurring variants of type A12 foot-and-mouth disease virus.
    Moore DM; Vakharia VN; Morgan DO
    Virus Res; 1989 Dec; 14(4):281-95. PubMed ID: 2483013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants.
    Saiz JC; Gonzalez MJ; Borca MV; Sobrino F; Moore DM
    J Virol; 1991 May; 65(5):2518-24. PubMed ID: 1707983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus.
    Baxt B; Vakharia V; Moore DM; Franke AJ; Morgan DO
    J Virol; 1989 May; 63(5):2143-51. PubMed ID: 2467993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, VP1, of foot-and-mouth disease virus A12.
    Robertson BH; Morgan DO; Moore DM
    Virus Res; 1984 Sep; 1(6):489-500. PubMed ID: 6085200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foot-and-mouth disease and its antigens.
    Bachrach HL
    Adv Exp Med Biol; 1985; 185():27-46. PubMed ID: 2416203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic variation among foot-and-mouth disease virus type A field isolates of 1997-1999 from Iran.
    Marquardt O; Freiberg B
    Vet Microbiol; 2000 Jun; 74(4):377-86. PubMed ID: 10831859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of foot-and-mouth disease virus C3 Resende to immunological pressure exerted in vitro by antiviral polyclonal sera.
    Schiappacassi M; Rieder Rojas E; Carrillo E; Campos R
    Virus Res; 1995 Apr; 36(1):77-85. PubMed ID: 7542827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.
    Parry NR; Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1493-503. PubMed ID: 2471812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies to an Indian strain of type A foot-and-mouth disease virus.
    Tosh C; Venkataramanan R; Pattnaik B; Hemadri D; Sanyal A
    Acta Virol; 1999 Aug; 43(4):219-25. PubMed ID: 10749367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif.
    Brown F; Benkirane N; Limal D; Halimi H; Newman JF; Van Regenmortel MH; Briand JP; Muller S
    Vaccine; 1999 Aug; 18(1-2):50-6. PubMed ID: 10501234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino acid changes outside the G-H loop of capsid protein VP1 of type O foot-and-mouth disease virus confer resistance to neutralization by antipeptide G-H serum.
    Krebs O; Ahl R; Straub OC; Marquardt O
    Vaccine; 1993; 11(3):359-62. PubMed ID: 7680514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic heterogeneity of a foot-and-mouth disease virus serotype in the field is mediated by very limited sequence variation at several antigenic sites.
    Mateu MG; Hernández J; Martínez MA; Feigelstock D; Lea S; Pérez JJ; Giralt E; Stuart D; Palma EL; Domingo E
    J Virol; 1994 Mar; 68(3):1407-17. PubMed ID: 8107204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse.
    Barnett PV; Samuel AR; Pullen L; Ansell D; Butcher RN; Parkhouse RM
    J Gen Virol; 1998 Jul; 79 ( Pt 7)():1687-97. PubMed ID: 9680132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic variation of foot-and-mouth disease virus of serotype C during propagation in the field is mainly restricted to only one structural protein (VP1).
    Sobrino F; Martinez MA; Carrillo C; Beck E
    Virus Res; 1989 Dec; 14(4):273-80. PubMed ID: 2560293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites.
    Xie QC; McCahon D; Crowther JR; Belsham GJ; McCullough KC
    J Gen Virol; 1987 Jun; 68 ( Pt 6)():1637-47. PubMed ID: 2438378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of capsid protein VP1 of the viruses used for the production and challenge of foot-and-mouth disease vaccines in Spain.
    González M; Mateu MG; Martínez MA; Carrillo C; Sobrino F
    Vaccine; 1992; 10(11):731-4. PubMed ID: 1279905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites.
    Kitson JD; McCahon D; Belsham GJ
    Virology; 1990 Nov; 179(1):26-34. PubMed ID: 1699353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epitope mapping of foot-and-mouth disease virus with neutralizing monoclonal antibodies.
    Bolwell C; Clarke BE; Parry NR; Ouldridge EJ; Brown F; Rowlands DJ
    J Gen Virol; 1989 Jan; 70 ( Pt 1)():59-68. PubMed ID: 2471783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenic comparison of different foot-and-mouth disease virus types using monoclonal antibodies defining multiple neutralizing epitopes on FMDV A5 subtypes.
    Saiz JC; Gonzalez MJ; Morgan DO; Card JL; Sobrino F; Moore DM
    Virus Res; 1989 May; 13(1):45-60. PubMed ID: 2473578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of anti foot and mouth disease virus T and B cell responses in cattle immunized with a peptide representing ten amino acids of VP1.
    Zamorano PI; Wigdorovitz A; Pérez Filgueira DM; Escribano JM; Sadir AM; Borca MV
    Vaccine; 1998 Apr; 16(6):558-63. PubMed ID: 9569465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.